Piaskledin capsules 300mg, No. 30

- complex therapy of osteoarthritis of the knee and hip joints of the I-III stage.

- adjuvant therapy for periodontitis.

Inside, 1 capsule. per day, preferably in the morning with meals, drinking 250 ml of water. The course of treatment is 6 months. An increase in the duration and repeated courses of treatment is possible after consulting a doctor.

Active ingredients: avocado oil unsaponifiable compounds 100 mg, soybean oil unsaponifiable compounds 200 mg.

Excipients: butylhydroxitoluene 0.03 mg, colloidal silicon dioxide 7 mg.

Capsule shell composition:

Capsules body: titanium dioxide 2%, gelatin up to 100%.

Capsules cap: titanium dioxide 2%, gelatin up to 100%.

Binder solution (composition for capsule sealing): polysorbate-80 0.25 mg, gelatin 5.75 mg.

Composition of TekPrint Щ SW-9008 Black Ink for capsule marking: shellac, ethanol, isopropanol, butanol, propylene glycol, concentrated ammonia solution, potassium hydroxide, black iron oxide.

- hypersensitivity to the components of the drug;

- the period of pregnancy and breastfeeding;

- age up to 18 years.

Application during pregnancy and breastfeeding:

The use of the drug during pregnancy and breastfeeding is not recommended.

Tradename:

Piaskledin 300

Dosage form:

capsules

Composition for one capsule:

Active ingredients: avocado oil unsaponifiable compounds 100 mg, soybean oil unsaponifiable compounds 200 mg.

Excipients: butylhydroxitoluene 0.03 mg, colloidal silicon dioxide 7 mg.

Capsule shell composition:

Capsules body: titanium dioxide 2%, gelatin up to 100%.

Capsules cap: titanium dioxide 2%, gelatin up to 100%.

Binder solution (composition for capsule sealing): polysorbate-80 0.25 mg, gelatin 5.75 mg.

Composition of TekPrint Щ SW-9008 Black Ink for capsule marking: shellac, ethanol, isopropanol, butanol, propylene glycol, concentrated ammonia solution, potassium hydroxide, black iron oxide.

Description

capsules (type I) with a white cap and an opaque white body marked 'P 300'. The contents of the capsules are brown paste.

Pharmacotherapeutic group

bone and cartilage metabolism corrector

Code: ћ09ј’ј01

Pharmacological properties

Pharmacodynamics

A herbal preparation that regulates metabolic processes in cartilaginous tissue. Has a symptomatic anti-inflammatory, analgesic effect on the joints. It helps to slow down the degenerative process in the cartilage tissue of the joints, reduces joint pain associated with this process, and restores motor function. Experimental studies have shown that the drug has a regenerating effect on cartilage, stimulating collagen synthesis in articular chondrocytes. The action of unsaponifiable compounds of soybean oil and avocado oil increases collagen production and inhibits the stimulating effect of interleukin-1 (IL-1) on collagenase synthesis.

Unsaponifiable compounds of soybean oil and avocado oil:

- increase the production of a plasminogenesis activator inhibitor, thereby reducing cartilage damage, both indirectly through the stimulation of metalloproteinases, and by direct action on cartilage, activating the degradation of proteoglycans, which prevents cartilage destruction;

- increase the effect of transforming growth factor? i (TGF) in chondrocytes, which has powerful anabolic properties;

- regulate the synthesis of macromolecules of the intercellular substance of the articular cartilage, are a powerful stimulator of the synthesis of macromolecules of hyaline cartilage, as well as periodontal tissue, preventing tooth loss.

Indications for use

- complex therapy of osteoarthritis of the knee and hip joints of the I-III stage.

- adjuvant therapy for periodontitis.

Contraindications

- hypersensitivity to the components of the drug;

- the period of pregnancy and breastfeeding;

- age up to 18 years.

Application during pregnancy and breastfeeding:

The use of the drug during pregnancy and breastfeeding is not recommended.

Method of administration and dosage

Take 1 capsule per day, preferably in the morning with meals, with 250 ml of water. The course of treatment is 6 months. An increase in the duration and repeated courses of treatment is possible after consulting a doctor.

Overdose

To date, no cases of overdose of the drug Piaskledin 300 have been reported.

Side effect

It is extremely rare to increase the following laboratory parameters: transaminases, alkaline phosphatase, bilirubin and gamma-glutamyl transpeptidase.

Interaction with other medicinal products

Not described.

special instructions

At the initial stage of treatment, taking Piaskledin 300 can be combined with taking NSAIDs and / or analgesics.

Influence on the ability to drive vehicles and mechanisms

Does not affect activities requiring increased concentration of attention and speed of psychomotor reactions.

Release form

Capsules 300 mg.

15 capsules in a blister of aluminum foil coated with heat-resistant resin and polyvinyl chloride film.

1 or 2 blisters, together with instructions for use, are placed in a cardboard box.

Storage conditions

In a dark place at a temperature of 15 to 25 ? C.

Keep out of the reach of children!

Shelf life

3 years.

Do not use after the expiration date.

Manufacturer

Expansyans Laboratory, France

Legal address: 1 Place de Sezon 92048 Paris la Defense Cedex, France

Manufacturing address: Rue de Quatre Fill, 28230 Epernon, France